apixaban-bms-56224701

Description: Apixaban (formerly BMS56224701; BMS 56224701; BMS-56224701; trade name: Eliquis), an approved drug used to treat and prevent the formation of blood clots, is a highly selective, reversible, direct inhibitor of Factor Xa with potential anti-coagulant activity. It inhibits Factor Xa with a Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is used as an anticoagulant for the treatment of venous thromboembolic events. Factor Xa is the activated form of the coagulation factorthrombokinase. Inhibiting Factor Xa could offer an alternate method for anticoagulation. Direct Xa inhibitors are popular anticoagulants. Apixaban was approved in Europe in 2012 and in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It was developed in a joint venture by Pfizer and Bristol-Myers Squibb.

References: J Med Chem. 2007; 50(22):5339-56; J Thromb Haemost. 2008; 6(5):820-9; J Thromb Thrombolysis. 2010; 29(1):70-80.

Related CAS#: 1118765-14-2 (O-Demethyl apixaban sulfate)

BMS56224701; BMS 56224701; BMS 562247-01; Apixaban, BMS-56224701; brand name: Eliquis

Chemical Name: 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4, 5-dihydropyrazolo[5, 4-c]pyridine-3-carboxamide